Capripoxviruses (CaPVs) cause serious pox diseases of domesticated ruminants (Carn, [1993](#tbed12447-bib-0004){ref-type="ref"}). Comprising sheep pox virus (SPPV), goat pox virus (GTPV) and lumpy skin disease virus (LSDV), they are large, complex, double‐stranded DNA viruses within the genus *Capripoxvirus*, subfamily *Chordopoxvirinae*, family *Poxviridae* (Buller et al., [2005](#tbed12447-bib-0003){ref-type="ref"}). SPPV and GTPV are normally restricted to Asia and North Africa, although clinical cases of sheep pox have also been detected in Europe (Mangana et al., [2008](#tbed12447-bib-0009){ref-type="ref"}), and recently in Bulgaria and Greece (during 2013). Lumpy skin disease (LSD) occurs across Africa, and in recent years, LSDV has also been found in several countries of the Middle East (Tuppurainen and Oura, [2012](#tbed12447-bib-0012){ref-type="ref"}), including Turkey where more than 236 outbreaks have occurred since 2013 (ProMed 20130831.1915595).

The World Organization for Animal Health (OIE) classifies CaPVs as notifiable disease agents, and molecular diagnostic tests play an important role in monitoring the spread of these viruses in susceptible livestock. A range of conventional agarose‐gel‐based polymerase chain reaction (PCR) assays (Ireland and Binepal, [1998](#tbed12447-bib-0006){ref-type="ref"}; Heine et al., [1999](#tbed12447-bib-0005){ref-type="ref"}; Markoulatos et al., [2000](#tbed12447-bib-0010){ref-type="ref"}; Tuppurainen et al., [2005](#tbed12447-bib-0013){ref-type="ref"}; Zheng et al., [2007](#tbed12447-bib-0014){ref-type="ref"}), or real‐time PCR assays (Balinsky et al., [2008](#tbed12447-bib-0001){ref-type="ref"}; Bowden et al., [2008](#tbed12447-bib-0002){ref-type="ref"}; Stubbs et al., [2012](#tbed12447-bib-0011){ref-type="ref"}) are used in diagnostic laboratories. However, poorly equipped laboratories often face difficulties accessing these molecular techniques (particularly real‐time PCR) that are reliant upon expensive and relatively fragile equipment. In particular, the ability to perform nucleic acid‐based tests such as PCR in field settings has proven to be a challenging goal largely due to the reliance upon pre‐processing of samples (nucleic acid extraction), the lack of stable reagents that are suitable for use in environments where it is not possible to maintain a cold chain (King et al., [2008](#tbed12447-bib-0007){ref-type="ref"}) and the cost of the field equipment. The Enigma Field Laboratory (FL) is a hardware platform which undertakes nucleic acid extraction, PCR thermocycling and analysis of data without user intervention, which has been applied for the detection of other notifiable diseases such as foot‐and‐mouth disease (Madi et al., [2012](#tbed12447-bib-0008){ref-type="ref"}). The aim of this study was to optimize and evaluate a mobile PCR platform for the simple detection of CaPV DNA.

This study utilized the real‐time PCR primers, probes, master mixes and cycling conditions that have been previously described (Bowden et al., [2008](#tbed12447-bib-0002){ref-type="ref"}). Pilot studies were undertaken to assess the performance of newly developed lyophilized PCR reagents that were prepared and assembled into assay cartridges by Enigma Diagnostics (Salisbury, UK). A decimal dilution series (Neat to 10^−10^) of DNA prepared from an LSDV isolate (Israel LSD‐07 POX‐V1‐07‐08, isolated from naturally infected cattle in 2007) was prepared in nuclease‐free water containing carrier RNA (1 *μ*g ml^−1^). In these experiments, 5 *μ*l of each dilution was mixed with 20 *μ*l of nuclease‐free water and this was used to re‐suspend the lyophilized reagent pellets prepared by Enigma Diagnostics. This 25 *μ*l suspension was then transferred into a 96‐well PCR plate. For the conventional wet reagents, 2 *μ*l of DNA was added to 18 *μ*l of diagnostic assay mastermix (Bowden et al., [2008](#tbed12447-bib-0002){ref-type="ref"}) prior to transfer into 96‐well PCR plate. This initial laboratory validation of lyophilized reagents was carried out on the Mx3005P quantitative PCR machine (Stratagene). Parallel testing demonstrated an improved analytical sensitivity of one log~10~ for the lyophilized reagents when compared to the reference test (Fig. [1](#tbed12447-fig-0001){ref-type="fig"}a). This one log~10~ increase in analytical sensitivity was maintained when the new lyophilized assay was applied to a decimal dilution series (10^−1^--10^−10^) of Israel LSD‐07 POX‐V1‐07‐08 virus prepared in 10% w/v homogenized cattle skin suspensions and run in full, including DNA extraction on the Enigma FL (Fig. [1](#tbed12447-fig-0001){ref-type="fig"}b). For the above comparison, one aliquot per dilution was extracted on the MagNA Pure LC Robot (Roche) using the Total Nucleic Acid Isolation kit (Roche) following manufacturer guidelines, followed by real‐time PCR performed using wet reagents assayed on the Mx3005P quantitative PCR machine (Stratagene) (reference test). The extraction and real‐time PCR for the second aliquot (0.5 ml) was performed in a complete automated cycle on the Enigma FL.

![Comparative analytical sensitivity of the lyophilized PCR assay used to detect CaPV DNA. (a) A decimal dilution series of CaPV DNA (isolate Israel LSD‐07 POX‐V1‐07‐08) tested using wet reagents (●) and lyophilized reagents (○) with a laboratory‐based PCR machine (Mx3005P, Stratagene). Points represent mean C~T~ from duplicate determinations where the maximum C~T~ range of duplicates was 1.53. (b) Comparison of a decimal dilution series of a CaPV isolate DNA (Israel LSD‐07 POX‐V1‐07‐08) spiked into skin suspensions assayed using wet PCR reagents (○, Mx3005P) compared to lyophilized PCR reagents and nucleic acid extraction employed on the Enigma FL (●). Points represent mean C~T~ from duplicate determinations for the wet PCR assay (\* data point represents a single where the duplicate sample generated a no C~T~ result), while only single values are shown for the samples tested on the Enigma FL.](TBED-64-994-g001){#tbed12447-fig-0001}

The suitability of this assay to detect CaPV DNA in clinical samples was evaluated using archived field and experimental samples held at the OIE Reference Laboratory for LSDV and GPV/SPV (The Pirbright Institute, UK) and the National Veterinary Reference Laboratory in Tanzania (Tanzania Veterinary Laboratories Agency‐TVLA). Fourteen clinical samples (Table [1](#tbed12447-tbl-0001){ref-type="table-wrap"}), comprising nine from two experimentally infected animals where cattle had been infected with LSDV Neethling strain (VN83 and VN84), and five from field samples submitted to The Pirbright Institute were used. Five additional skin scrapings from the TVLA archive were analysed within East African laboratory settings. For each sample, one duplicate was extracted and assayed using the established reference test (Bowden et al., [2008](#tbed12447-bib-0002){ref-type="ref"}) whilst for the second duplicate the extraction and real‐time PCR was performed on the Enigma FL. There was complete concordance between positive results (*n* = 19) and negative results (*n* = 3) generated on the Enigma FL and the standard laboratory pipelines (Table [1](#tbed12447-tbl-0001){ref-type="table-wrap"}). Opportunistic testing of samples collected from a Holstein--Friesian cross‐dairy cow on a small holder farm in Morogoro, Tanzania, displaying clinical signs of LSD (Fig. [2](#tbed12447-fig-0002){ref-type="fig"}) was also undertaken. Two samples comprising EDTA blood and skin scrapings were tested; skin scrapings were processed using a field‐based tissue processing kit (Svanodip^®^ Ag extraction kit; prior to being added into the Engima FL sample loading chamber, whilst EDTA blood was added directly to the sample chamber). Both specimens were positive for CaPV DNA using the Enigma FL. It should be noted that the current diagnostic reference test (Bowden et al., [2008](#tbed12447-bib-0002){ref-type="ref"}) utilizes a conservative cut‐off C~T~ value of \<37 to define a positive result. However, for this study, all C~T~ values are reported because amplification of CaPV in animals with late infection may generate weak values that would be missed with a cut‐off of 37. Suitable negative controls were also included in the data set to confirm the absences of any false amplification.

###### 

Performance of the lyophilized PCR system (Enigma FL) compared to the laboratory‐based PCR pipeline (Reference Test) using clinical samples collected from field cases and experimental infection studies

                                                           Sample ID         Species   Sample type   Enigma FL C~T~   Reference test C~T~
  -------------------------------------------------------- ----------------- --------- ------------- ---------------- ---------------------
  Experimental infection                                   VN83 11DPI        Cattle    Blood         33               35.74
  VN83 14DPI                                               Cattle            Ocular    39            35.93            
  VN83 16DPI                                               Cattle            Saliva    43            33.38            
  VN83 25DPI                                               Cattle            Nasal     36            32.90            
  VN83 28DPI                                               Cattle            Saliva    39            33.83            
  VN83 37DPI                                               Cattle            Scabs     18            15.71            
  VN84 12DPI                                               Cattle            Blood     34            34.71            
  VN84 14DPI                                               Cattle            Ocular    38            34.86            
  VN84 22DPI                                               Cattle            Scabs     17            16.91            
  Field samples                                            BUL/V713‐1 2013   Sheep     Blood         34               29.96
  BUL/V713‐3 2013                                          Sheep             Blood     33            28.93            
  MON/V107‐1 2007                                          Sheep             Blood     16            11.50            
  MON/V107‐3 2007                                          Sheep             Scabs     16            12.53            
  VIET/21030‐2 2005                                        Goat              Scabs     22            18.99            
  TAN/TVLA 1 GRS[a](#tbed12447-note-0001){ref-type="fn"}   Cattle            Scabs     16            16.12            
  TAN/TVLA 2 NS[a](#tbed12447-note-0001){ref-type="fn"}    Cattle            Scabs     31            31.23            
  TAN/TVLA 3 MR[a](#tbed12447-note-0001){ref-type="fn"}    Cattle            Scabs     26            26.34            
  TAN/TVLA 4 MS[a](#tbed12447-note-0001){ref-type="fn"}    Cattle            Scabs     18            18.18            
  TAN/TVLA 5 GM[a](#tbed12447-note-0001){ref-type="fn"}    Cattle            Scabs     34            34.14            
  TAN/Morogoro[b](#tbed12447-note-0002){ref-type="fn"}     Cattle            Blood     35            Not tested       
  TAN/Morogoro[b](#tbed12447-note-0002){ref-type="fn"}     Cattle            Scabs     19            Not tested       
  Control                                                  UKG Negative      Cattle    Blood         No C~T~          No C~T~
  UKG Negative                                             Sheep             Blood     No C~T~       No C~T~          
  UKG Negative                                             Cattle            Skin      No C~T~       No C~T~          

Five samples were skin nodule scrapings from separate cattle with clinical LSD from Mwika Village, Kilimanjaro, Tanzania.

Field samples from Morogoro, Tanzania, collected and analysed *in situ*.
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![Holstein--Friesian cross‐dairy cow displaying clinical signs of lumpy skin disease (LSD) on a farm in Morogoro, Tanzania, from which field samples (EDTA blood and skin nodule scrapings) were tested.](TBED-64-994-g002){#tbed12447-fig-0002}

These data show that a mobile PCR platform can rapidly detect CaPVs from suspect cases, within 60 minutes of sample collection, offering a sensitive molecular technology that can be deployed into field settings. Furthermore, the comparative data for the lyophilized reagents demonstrate that it is possible to generate a stabilized assay with equivalent (or better) performance compared with the wet‐assay format. This current assay format represents the results of a collaborative research project that was undertaken to highlight the potential of these technologies for diagnostic use. Future validation to include a greater sample data set would increase confidence in the test and could be combined with optimization of the DNA extraction steps to bring its performance in line with that of a standard laboratory extraction robot. Further availability of this particular assay (via commercial sources), as well as other tests that might also exploit this format, will be dependent upon demand and interest from customers.
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